A Combination of Low-Dose Systemic Etretinate and Topical Calcipotriol/Betamethasone Dipropionate Treatment for Hyperkeratosis and Itching in Olmsted Syndrome Associated with a TRPV3 Mutation
May 2017
in “
Journal of dermatological science
”
TLDR The combined treatment effectively managed severe skin issues in Olmsted syndrome.
The document discussed a treatment approach for Olmsted syndrome (OS), a rare genetic skin disorder characterized by symmetrical keratoderma and hyperkeratotic plaques, often associated with TRPV3 mutations. The study explored the efficacy of combining low-dose systemic etretinate with topical calcipotriol/betamethasone dipropionate to manage hyperkeratosis and itching in OS patients. This combination therapy aimed to alleviate the severe skin manifestations and improve the quality of life for individuals suffering from this condition.